Pathophysiology, clinical presentation, and treatment of coma and acute kidney injury complicating falciparum malaria

Katherine Plewes⁵,⁶, Gareth D.H. Turner⁷,⁸, and Arjen M. Dondorp⁵,⁶

Purpose of review
Cerebral impairment and acute kidney injury (AKI) are independent predictors of mortality in both adults and children with severe falciparum malaria. In this review, we present recent advances in understanding the pathophysiology, clinical features, and management of these complications of severe malaria, and discuss future areas of research.

Recent findings
Cerebral malaria and AKI are serious and well recognized complications of severe malaria. Common pathophysiological pathways include impaired microcirculation, due to sequestration of parasitized erythrocytes, systemic inflammatory responses, and endothelial activation. Recent MRI studies show significant brain swelling in both adults and children with evidence of posterior reversible encephalopathy syndrome-like syndrome although targeted interventions including mannitol and dexamethasone are not beneficial. Recent work shows association of cell-free hemoglobin oxidation stress involved in the pathophysiology of AKI in both adults and children. Paracetamol protected renal function likely by inhibiting cell-free-mediated oxidative stress. It is unclear if heme-mediated endothelial activation or oxidative stress is involved in cerebral malaria.

Summary
The direct causes of cerebral and kidney dysfunction remain incompletely understood. Optimal treatment involves prompt diagnosis and effective antimalarial treatment with artesunate. Renal replacement therapy reduces mortality in AKI but delayed diagnosis is an issue.

Keywords
Cerebral malaria, malaria-associated acute kidney injury, pathophysiology, treatment

INTRODUCTION
Severe malaria incidence is approximately two million cases with nearly 430,000 deaths annually [1]. It is a medical emergency characterized by multisystem disease with different clinical manifestations between adults and children. However, recent studies show that cerebral involvement, kidney dysfunction, and acidosis are independent predictors of mortality in both adults and children (Fig. 1)[2,3]. This is supported by a meta-analysis of children with severe malaria that found prognostic indicators with the strongest association with death to be acute kidney injury (AKI) (odds ratio 5.96, 95% confidence interval, CI: 2.9–12.11) and coma (4.83, 95% CI: 3.11–7.5) [4].

Cerebral malaria is a clinical syndrome of impaired consciousness associated with malaria in the absence of hypoglycemia, convulsions, drugs, and nonmalarial causes characterized by unrousable coma defined by a Glasgow Coma Score less than 11 (adults) [5] or Blantyre Coma Score less than 3 (children) [6–8]. Two large intervention trials in Asian adults and African children with severe malaria

*Faculty of Tropical Medicine, Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand, †Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, ‡Department of Cellular Pathology, John Radcliffe Hospital and §Nuffield Department of Clinical Medicine, Center for Tropical Medicine and Global Health, University of Oxford, Oxford, UK

Correspondence to Katherine Plewes, Clinical Investigator, Mahidol-Oxford Tropical Medicine Research Unit (MORU), Clinical Assistant Professor, UBC Division of Infectious Diseases, Heather Pavilion East 452D, Vancouver General Hospital, 2733 Heather Street, Vancouver, British Columbia, V5Z 3J5, Canada. Tel: +1 604 875 4588; fax: +1 604 875 4013; e-mail: Katherine@tropmedres.ac

Curr Opin Infect Dis 2018, 31:69–77
DOI:10.1097/QCO.0000000000000419
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
found that 54% of adult and 34% of pediatric patients had cerebral malaria [9,10]. AKI in severe falciparum malaria is caused by acute tubular necrosis and defined as a creatinine more than 265 μmol/l or urea more than 20 mmol/l [6]. In adults with severe malaria, AKI develops in up to 40% of patients, whereas in children, the incidence is historically reported at approximately 10% [9,10]. As the WHO definition does not define AKI adequately for pediatric malaria, the reported incidence of AKI in children is likely underestimated. The recent Kidney Disease: Improving Global Outcomes (KDIGO) classification standardizes AKI for clinical practice and research [11]. In adult severe malaria, 58% had AKI as defined by KDIGO, of whom 40% died, accounting for 71% of overall mortality [12]. Among children with severe malaria, 46% had AKI as defined by KDIGO, of whom 12–24% died with increasingly severe AKI [13]. In two large multicenter studies, approximately 25% of children with severe malaria had increased blood urea nitrogen, accounting for roughly 50% of total deaths [10,14]. These studies imply that AKI complicating pediatric severe malaria has been previously underdiagnosed [13].

Notably, the majority of patients surviving these complications have complete recovery after appropriate treatment. The direct cause of coma and AKI complicating severe malaria are incompletely understood but likely share common pathophysiological mechanisms. This review will highlight recent developments in our understanding of the pathophysiologic and pathologic processes associated with cerebral malaria and malaria-associated AKI in addition to the clinical presentation, diagnosis and treatments of these complications.

**PATHOGENESIS**

Severe malaria is predominantly caused by *Plasmodium falciparum* because of its ability to induce infected red blood cell (RBC) cytoadherence to the
vascular endothelium and consequent end-organ dysfunction. Other plasmodium species can cause severe disease and AKI [15], although their ability to cause coma is debated [6].

**Microvascular obstruction**

Parasites developing within the infected RBC transport *P. falciparum* erythrocyte membrane protein 1 (*PfEMP1*) to the RBC membrane functioning as a key ligand for cytoadherence [16]. *PfEMP1* is expressed on RBC protrusions, or ‘knobs’, that confer points of attachment to the endothelium. *PfEMP1* is strain specific, encoded by a highly variable var gene family, which provides antigenic variation for immune evasion and differential endothelial receptor binding. CD36 is an endothelial receptor constitutively expressed on most vascular beds [17]. The key endothelial receptor in the brain is intercellular adhesion molecule-1 [18]. Recent studies have identified endothelial protein C receptor as an important receptor in the brain that binds to a specific *PfEMP1* domain (CIDRα1) [19*,20–22*]. Cytoadhesion results in sequestration of parasitized RBCs in the capillaries and postcapillary venules causing heterogeneous blockage of the microcirculation and tissue hypoxia [23]. In addition to flow obstruction by sequestered parasitized RBCs, microcirculatory flow is thought to be further compromised by increased rigidity of both infected and uninfected RBCs and clumping of infected RBCs (platelet-mediated autoagglutination) and uninfected RBCs adhering to infected RBCs (rosette formation) [24].

Direct visualization of microvascular obstruction is observed in the retina of adults and children with cerebral malaria, termed ‘malaria retinopathy’ [25,26]. Cerebral blood flow is not decreased in adults [27,28]. Intracranial pressure is often increased in children, but less so in adult patients [29,30]. Indirect assessment of sequestration via estimated total parasite biomass, measured by *P. falciparum* histidine rich protein 2, was shown to contribute to AKI in adults with severe malaria [31]. Autopsy studies of adults and retinopathy-positive children dying from cerebral malaria show prominent sequestration in the brain microvasculature compared to adults with fatal noncerebral malaria and retinopathy-negative children [32,33]. Post-mortem studies report sequestration of parasitized RBCs in renal glomerular and peritubular capillaries in adults and children [32,34].

**Endothelial activation**

Microvascular obstruction-induced tissue hypoxia is compounded by microvascular dysfunction [35,36] and increased oxygen demand [36,37]. In adults with cerebral malaria, there is endothelial and astroglial activation in the brain [18], with variable inflammatory responses [38] and mild functional change to the blood–brain barrier [39,40]. In children with strictly defined retinopathy-positive cerebral malaria, breakdown of the endothelial barrier is observed particularly in areas of sequestration [32]. Patterns of histopathological change within the brain in cerebral malaria vary between adults and children, with less inflammatory cellular infiltrates and edema in adult cases [41,42]. A recent pediatric autopsy study found that HIV coinfection influences histopathology, increasing the degree of platelet and monocyte infiltration around damaged microvasculature [43].

In a recent MRI study of similarly defined children, 35% had evidence of brain swelling most commonly in fatal cases implicating brainstem herniation as the cause of death [44]. Another recent serial MRI study in India including adults and children found that 50% of patients had evidence of brain swelling with posterior vasogenic edema and vascular congestion in the basal nuclei [45*]. All patients had rapid clinical improvement and radiological reversibility with hallmarks suggestive of posterior reversible encephalopathy syndrome. The exact cause of the brain swelling is yet unclear.

Studies of patients with severe malaria having AKI show reduced renal cortical blood flow [46], increased kidney size [47], and endothelial changes in both glomerular and peritubular capillaries on histopathology [34]. Cell-free hemoglobin and lipid peroxidation markers are strongly associated with AKI and renal replacement therapy (RRT) requirement in adults with severe malaria [12*]. In children with severe malaria, an elevated heme-to-hemopexin ratio was associated with hemoglobinuria, stage 3 AKI, and 6-month mortality [48*].

**Cytokines**

There is an imbalance of proinflammatory and anti-inflammatory responses in severe malaria [49]. The role of cytokines and chemokines in cerebral malaria has been recently reviewed [50]. However, many of these studies are in the murine experimental cerebral malaria model, the relevance of which has been questioned [51]. Conflicting evidence has emerged from human studies as to the association between cerebral malaria and levels of numerous cytokines such as tumor necrosis factor α (TNFα) [49,52–56]. Although cytokines and/or chemokines are clearly involved in the pathogenesis of malarial fever and may be associated with disease severity
and/or cerebral malaria, it is not established that they are a cause of coma.

The role of cytokines and chemokines in the pathophysiology of AKI in severe malaria was recently highlighted. Plasma-soluble urokinase-type plasminogen activator receptor, a marker of immune activation, was independently associated with AKI and RRT requirement [31]. Previously, it was shown that TNFα, but not interleukin (IL)6 or IL6:IL10 ratio, was associated with AKI suggesting that TNFα may induce localized renal tubular cell injury [57].

CLINICAL FEATURES

The clinical presentation of cerebral malaria is diffuse symmetrical encephalopathy with fever and absent or few focal neurological signs. In children, coma can rapidly develop after fever onset (mean, 2 days) [7]. In adults, coma is typically gradual with increasing drowsiness, confusion, obtundation, and high fevers (mean duration, 5 days). Convulsions are present in approximately 15% of adults and 80% of children with severe malaria [9,10] and frequently herald development of coma. Patients may recover full consciousness after a convulsion, thus transient postictal coma must be excluded [6]. Multiple convulsions are common and up to 50% of comatose children have subclinical seizures or status epilepticus. Ocular funduscopic findings include vessel color change, macular and extramacular whitening, and white-centered retinal hemorrhages [58] (Fig. 2).

Among survivors, the median time to coma recovery is roughly 24 h in children and 48 h in adults [9,10]. Retinal abnormalities resolve with no residual visual deficit. Neurologic sequelae occur in less than 1% of adults but up to 12% of children in the quinine-therapy era, including hemiplegia, cortical blindness, aphasia, and cerebellar ataxia [59]. Studies suggest that neurologic deficits may reflect slow neurological recovery [10,60]. Postmalaria neurological syndrome is self-limiting [61]; however, longer term neurological sequelae, including cognitive deficits and epilepsy, are reported among children [62,63*].

The majority of malaria patients have risk factors for developing AKI, including volume depletion, hypoalbuminemia, male sex, previous AKI, concomitant bacterial sepsis, blackwater fever (BWF), or comorbidity, such as, diabetes. Severe intravascular hemolysis and hemoglobinuria in severe malaria, with or without AKI, is known as BWF. Although oliguria clinically indicates decreased function with a prerenal component, up to 80% of patients with malaria have nonoliguric AKI [64–66]. Thus, the clinical diagnosis will capture established anuric AKI but will underdiagnose moderate AKI and delay diagnosis. AKI complicating severe malaria can be categorized into four groups:

1. Few severity criteria with prerenal AKI that resolves with fluids.
2. Several severity criteria including AKI that resolves without RRT.
3. Progressive AKI that resolves with antimalarial treatment and RRT.
4. Multiorgan dysfunction, often with anuric AKI and cerebral malaria, who die prior to or during RRT with hemodynamic shock and/or respiratory failure.
DIAGNOSIS

Any comatose patient with a history of fever and/or travel to malaria-endemic regions must be considered to have cerebral malaria until proven otherwise. In children, febrile convulsions should be distinguished from cerebral malaria, wherein coma will persist beyond 1 h after anticonvulsive treatment is administered. Absence of fever does not rule out malaria. Antimalarial treatment should not be delayed in severely ill patients if diagnostics are unavailable or delayed.

Parasitological diagnosis is by microscopy of stained thin and thick blood smears. A rapid diagnostic test for parasite antigens can be performed if microscopy is unavailable. Patients may have a low circulating parasitemia because of sequestration, thus a low parasitemia is not reassuring [67]. In high-transmission settings, children with partial immunity tolerate higher parasitemia without severe symptoms and may be asymptomatic at low parasitemia. A parasitemia of more than 1000/µl in African children with cerebral malaria is associated with fatal outcomes [7].

Fundusccopy for malaria retinopathy improves specificity for diagnosis of cerebral malaria and is prognostic in patients with severe malaria [26,68,69] (Fig. 2). Alternative causes of coma must be ruled out including hypoglycemia, and bacterial, fungal, or viral meningoencephalitis. Lumbar puncture does not increase mortality in stable, comatose children with suspected cerebral malaria even when MRI brain swelling or papilledema is present [70*].

There is no robust prognostic risk model or biomarker that can predict AKI or RRT requirement [71,72*]. All patients with malaria should be considered at risk of developing AKI. To improve outcomes, early diagnosis and management is critical. AKI diagnosis requires quantification of creatinine (or urea) or observing low urine volume (<0.5 ml/kg/h) for 6 h (Fig. 3) [6,11]. Urine output is difficult to accurately assess in malaria endemic countries and may delay diagnosis. As the WHO creatinine threshold is not applicable to children, the diagnosis of AKI must be considered using all available patient data. The KDIGO AKI definition of a creatinine rise of ≥0.5 mg/dl (or ≥0.44 mmol/l) in 48 h is too sensitive. The modified creatinine threshold is an acceptable option for children [73].

TREATMENT

The two key pillars of severe malaria treatment are prompt antimalarial treatment and supportive management. Adjunctive therapies targeted at the underlying pathophysiology are unproven.

Antimalarial treatment

Two landmark trials in patients with severe malaria definitively showed that intravenous artesunate reduced mortality by 35% and 23% in adults and children, respectively, compared to quinine [9,10]. Intravenous artesunate is now the first-line treatment for severe malaria as recommended by the WHO. Artemether and quinine are the second-line therapies [74]. The mechanism of improved survival over quinine is the rapid cidal activity of artesunate on young ring forms, preventing parasite maturation and sequestration [75]. Once the patient is able to take oral medication, and after a minimum of 24 h of artesunate, an oral artemisinin-based combination therapy can be initiated to complete the treatment.

Supportive treatment

Despite the best available artemisinin therapy for malaria, mortality remains unacceptably high and supportive management is key to reducing this. Comatose patients require endotracheal intubation with mechanical ventilation for airway protection. Rapid sequence intubation should be performed to prevent transient hypercapnia and increased intracranial pressure. Routine care should be implemented including regular turning, lateral positioning (‘recovery position’), and catheterization. Nasogastric tube insertion and suctioning may protect against aspiration, however, enteral feeding in nonintubated patients should be delayed (>60 h) because of increased risk of aspiration pneumonia [76].

The majority of children with cerebral malaria experience convulsions. Glucose replacement to ensure euglycemia and fever control with paracetamol are important. Prophylactic anticonvulsant therapy is not recommended. A randomized controlled trial (RCT) of phenobarbital in pediatric cerebral malaria showed increased mortality, likely caused by respiratory depression [77].

Fluid management and nephrotoxic drug avoidance are cornerstones for management of malaria-associated AKI. Cautious fluid management is important, as patients with AKI are not necessarily hypovolemic and are at high risk of developing pulmonary edema [78–81]. Rapid infusions may exacerbate intracranial hypertension and precipitate cerebral herniation. The large multicenter Fluid Expansion as Supportive Therapy study of African children with severe febrile illness showed a relative risk for death of 1.59 (95% CI: 1.10–2.31) with fluid bolus therapy among those with malaria [14]. The WHO recommends individualized restrictive fluid management, keeping the patient slightly dry, using slow infusion of isotonic crystalloids [74]. Patients with BWF require creatinine and hemoglobin
monitoring as resulting severe anemia requires whole blood transfusion.

Treatment of malaria-associated AKI with RRT reduces mortality from 75 to 26% [64]. In general, RRT is urgently indicated when biochemical disturbances and volume overload refractory to conventional therapy are present. The additional thresholds included in the WHO malaria guidelines are based on findings that anuria and elevated or rapidly rising creatinine are sensitive indicators for RRT [6,64]. As AKI in malaria rapidly progresses and is often compounded by multiorgan dysfunction, early RRT is recommended. Although intermittent hemodialysis and continuous venovenous hemofiltration have been shown to be superior to peritoneal dialysis in adults with severe malaria [82], in the absence of

![FIGURE 3. General management of AKI in malaria based on KDIGO guidelines.](image-url)

- **History** including preadmission medications, comorbidities, and physical examination focusing on volume status and signs of concomitant sepsis.
- **Laboratory tests** including serum creatinine, urea, electrolytes, and full blood count.
- **Stage** using KDIGO staging criteria. If baseline creatinine is unknown, estimate using back-calculation of MDRD equation (>19 years) or Swartz equations (≤18 years).
- **Urinary bladder catheterization** to monitor initial urine output if unconscious. If ambulating, urine should be collected to monitor output. Patients should be managed according to AKI stage, as stage correlates with increased morbidity and mortality.
- **Daily creatinine and urine output** to monitor change in AKI stage severity and guide management.
- **Additional investigations** to assess AKI etiology: urine analysis, sediment microscopy, creatinine, and sodium; renal ultrasound to assess kidney size, presence of pyelonephritis, and inferior vena cava filling as a gauge of volume status; AKI biomarkers if applicable. Nephrotoxic drugs, that is, aminoglycosides, should be avoided whenever possible. Discontinuation of nephrotoxic drugs may assist with determining AKI etiology. If resources permit, monitor hemodynamic variables. Static central venous pressure is of limited value but recommended target is 0 to +5 cmH₂O. Arterial pulse pressure as a dynamic variable may be more useful to gauge response to fluid administration. Early referral to center with RRT, particularly if one indication for RRT is present. Patients with multiorgan dysfunction are recommended to receive urgent dialysis within 2 h [6]. Patients should be evaluated 3 months after AKI resolution to monitor resolution of kidney function and/or development of chronic kidney disease. AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes; MDRD, modification of diet in renal disease [11]; RRT, renal replacement therapy. Reprinted from Kidney International Supplements 2, Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, KDIGO Clinical Practice Guideline for Acute Kidney Injury. Page 25. Copyright (2012) with permission from Elsevier.
hemodialysis, life-saving peritoneal dialysis should be initiated if this is the only modality available [83]. RRT has also been shown to be effective in the management of malaria-associated AKI in pediatric patients [84]. Many adjunctive therapies have been suggested, mainly driven by studies in murine experimental cerebral malaria. However, none has proven benefit in humans. Evidence for exchange transfusion and the more recently employed RBC exchange transfusion remains limited [85*,86,87]. Mannitol [88,89], steroids [90,91], and monoclonal antibodies to TNF [54,56] are not recommended as treatments in cerebral malaria as studies show no benefits and potential harm. Furosemide and mannitol are ineffective in preventing and treating AKI and BWF, respectively, and may be harmful [92,93]. On the basis of the ability of paracetamol to inhibit hemoprotein-mediated AKI [94], a recent RCT of paracetamol in Bangladeshi adults with severe malaria found that acetaminophen improved kidney function and reduced the development of AKI, particularly in patients with high cell-free hemoglobin levels at enrollment [95*,96]. Larger studies of paracetamol in adults and children with malaria are currently ongoing to further assess this renoprotective effect.

CONCLUSION

Cerebral malaria and AKI complicating severe malaria are prognostic for mortality in both adults and children. Microvascular obstruction and endothelial dysfunction are common mechanisms for both of these complications. Future study of adjunctive therapies should target reducing sequestration, improving endothelial function, and reducing hemoglobin-mediated oxidative stress.

Acknowledgements

None.

Financial support and sponsorship

This work was supported by the Wellcome Trust of Great Britain.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. World Health Organization. World Malaria Report. 2016 September 2, 2017. Available from: http://www.who.int/malaria/publications/world-malaria-report-2016/en/

2. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151–157.

3. von Seideln L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in African children: findings from a large randomized trial. Clin Infect Dis 2012; 54:1080–1090.

4. Sypniewska P, Duda JF, Locatelli I, et al. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med 2017; 15:147–163.

5. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81–84.

6. World Health Organization. Severe malaria. Trop Med Int Health 2014; 19(Suppl 1):7–131.

7. Molyneux ME, Taylor WE, Winima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71:441–459.

8. Newton CR, Chokwe T, Scheelgen JA, et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:161–165.

9. Dondorp A, Nosten F, Stepaniwka K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717–725.

10. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1947–1957.

11. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2:1–129.

12. Plewes K, Kingston HGF, Ghose A, et al. Cell-free hemoglobin mediated oxidative stress is associated with acute kidney injury and renal replacement therapy in severe falciparum malaria: an observational study. BMC Infect Dis 2017; 17:313–324.

Detailed observational pathophysiological study suggesting that cell-free hemoglobin and lipid peroxidation are associated with AKI and RRT requirement in Bangladeshi adults with severe malaria.

13. Conroy AL, Hawkes M, Elphinstone RE, et al. Acute kidney injury is common in pediatric severe malaria and is associated with increased mortality. Open Forum Infect Dis 2016; 3:fow046.

Detailed observational study of 180 Ugandan children with severe malaria found that 46% had AKI as defined by KDIGO, of whom 12–24% died with increasingly severe AKI and 50% evolved or developed AKI after admission.

14. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483–2495.

15. Anstey NM, Douglas NM, Poepsogiro JD, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 2012; 80:151–201.

16. Magowan C, Woollis W, Anderson L, Leech J. Cytadherence by Plasmodium falciparum-infected erythrocytes is correlated with the expression of a family of variable proteins on infected erythrocytes. J Exp Med 1988; 168:1307–1320.

17. Cooke B, Coppel R, Wahlgren M. Falciparum malaria: sticking up, standing around; and then dropping dead. Nat Rev Microbiol 2006; 4:395–410.

18. Turner GD, Morrison H, Jones M, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994; 145:151–157.

19. Barnabe M, Danziger SA, Avril M, et al. Severe adult malaria is associated with specific PIEMP1 adhesion types and high parasite biomass. Proc Natl Acad Sci USA 2016; 113:E3270–E3279.

Translational study showing that parasites isolated from adults with severe malaria exhibit specific var genes/PIEMP1 transcripts associated with parasite biomass and activated protein C/endothelial protein C receptor pathway disruption.

20. Gillrie MR, Avril M, Bazerj AJ, et al. Diverse functional outcomes of Plasmodium falciparum infection in the long term. PLoS Pathog 2015; 11:e1005031.

21. Moxon CA, Wassmer SC, Milner DA Jr, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite biomass and activated protein C/endothelial protein C receptor pathway disruption.

22. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop 2004; 89:309–317.

23. Beare NA, Taylor TE, Harding SP, et al. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006; 75:790–797.
CNS infections

26. Maude RJ, Beare NA, Abu Sayeed A, et al. The spectrum of retinopathy in adults with Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2009; 103:665–671.

27. Clavier N, Rahimi F, Calagna P, et al. No evidence for cerebral hyperperfusion during cerebral malaria. Crit Care Med 1997; 25:628–632.

28. Warrell DA, White NJ, Veall N, et al. Cerebral anaerobic glycolysis and reduced cerebral oxygen transport in human cerebral malaria. Lancet 1988; 2:534–538.

29. Newton CR, Kirkham FJ, Winstonley PA, et al. Intracranial pressure in African children with cerebral malaria. Lancet 1991; 337:573–576.

30. Waller D, Crawley T, Nosten F, et al. Intracranial pressure in childhood cerebral malaria. Trans R Soc Trop Med Hyg 1991; 85:362–364.

31. Piewes K, Royakers AA, Hanson J, et al. Correlation of biomarkers for parasite burden and immune-mediated sequelae of acute kidney injury in severe falciparum malaria. Malar J 2014; 13:91–100.

32. Milner DA Jr, Whitten RO, Kamiza S, et al. The systemic pathology of cerebral malaria in African children. Front Cell Infect Microbiol 2014; 4:1–13.

33. Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69:345–352.

34. Nguausangam S, Day NP, Hien TT, et al. A quantitative ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Trop Med Int Health 2007; 12:1037–1050.

35. Yeo TW, Hien ThA, Githii K, et al. Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis 2008; 198:602–608.

36. Yeo TW, Hien ThA, Githii K, et al. Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria. J Infect Dis 2013; 207:528–536.

37. Day NP, Hien TT, Ho VT, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996; 348:219–223.

38. Madras KG, Warrell MJ, White NJ, et al. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119:385–401.

39. Davis TM, Suputtamongkol Y, Phillips RE, et al. The role of animal models for research on the systemic pathology of cerebral malaria in African children. Front Cell Infect Microbiol 2014; 4:1–13.

40. Seydel KB, Kampondeni SD, Valim C, et al. The systemic pathology of the brain in fatal Plasmodium falciparum malaria: relation to severity of infection. Am J Pathol 1985; 119:385–401.

41. Grau GE, Taylor TE, Molyneux ME, et al. The systemic pathology of cerebral malaria in African children. Front Cell Infect Microbiol 2014; 4:1–13.

42. Elphinstone RE, Conroy AL, Hawkes M, et al. The role of animal models for research on the systemic pathology of cerebral malaria in African children. Front Cell Infect Microbiol 2014; 4:1–13.

43. Day NP, Hien TT, Scholalardi T, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe children. J Infect Dis 1999; 180:1288–1297.

44. Sitprija V, Yonggthongni M, Poshayachinda V, Jr. Renal failure in patients with severe falciparum malaria. Am J Kidney Dis 1988; 11:1201–1204.

45. Altoﬁ O, Iqbal M, de Vries M, et al. Higher levels of plasma nGnRH in children with cerebral malaria. Neurosci Lett 2005; 376:255–258.

46. Doohoi B, Nnang M, Rufﬂe EM, et al. Cerebral anaerobic glycolysis and cerebral oxygen transport in children with severe falciparum malaria. Trop Med Int Health 2007; 12:1037–1050.

47. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med 2017; 376:11–20.

48. World Health Organization. World Health Organization Guidelines for the treatment of malaria. Third edition. Geneva: World Health Organization, 2015. Available from: http://www.who.int/malaria/publications/atoz/9789241549127/en/
81. Nguyen HP, Hanson J, Bethell D, et al. A retrospective analysis of the haemodynamic and metabolic effects of fluid resuscitation in Vietnamese adults with severe falciparum malaria. PLoS One 2011; 6:1–9.
82. Phu NH, Hien TT, Mai NT, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002; 347:895–902.
83. Mishra SK, Mahanta KC. Peritoneal dialysis in patients with malaria and acute kidney injury. Perit Dial Int 2012; 32:656–659.
84. Asinobi AO, Ademola AD, Aalo MA. Haemodialysis for paediatric acute kidney injury in a low resource setting: experience from a tertiary hospital in South West Nigeria. Clin Kidney J 2016; 9:63–68.
85. Calvo-Cano A, Gomez-Junyent J, Lozano M, et al. The role of red blood cell exchange for severe imported malaria in the artesunate era: a retrospective cohort study in a referral centre. Malar J 2016; 15:216–222.
86. Gyr K, Speck B, Ritz R, et al. Cerebral tropical malaria with blackwater fever. A current diagnostic and therapeutic problem [in German]. Schweiz Med Wochenschr 1974; 104:1628–1630.
87. Tan KR, Wiegand RE, Arguin PM. Exchange transfusion for severe malaria: evidence base and literature review. Clin Infect Dis 2013; 57:923–928.
88. Mohanty S, Mishra SK, Patnaik R, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis 2011; 53:349–355.
89. Namutangula B, Ndeze G, Byarugaba JS, Tumwine JK. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malar J 2007; 6:138–143.
90. Hoffman SL, Rustama D, Punjabi NH, et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J Infect Dis 1988; 158:325–331.
91. Warrell DA, Looareesuwan S, Warrell MJ, et al. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med 1982; 306:313–319.
92. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia 2010; 65:283–293.
93. Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. Br Med J 2008; 338:420–425.
94. Boutaud O, Moore KP, Reeder BJ, et al. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci USA 2010; 107:2699–2704.
95. Plewes K. Intravascular haemolysis, oxidative stress and acute kidney injury in severe falciparum malaria [DPhil]. University of Oxford, (Nuffield Department of Medicine; Green Templeton College.) University of Oxford, 2016
96. Plewes K, Kingston HWWT, Ghose A, et al., editors. Paracetamol as adjunctive treatment in severe and moderately severe falciparum malaria: An open label, randomised controlled trial. In: American Society of Tropical Medicine and Hygiene 65th Annual Meeting. Philadelphia, Pennsylvania, 2015.
97. Maude RJ, Plewes K, Dimock J, Dondorp AM. Low-cost portable fluorescein angiography. Br J Ophthalmol 2011; 95:1213–1215.